294 related articles for article (PubMed ID: 36127137)
1. Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review.
Ailani J; Kaiser EA; Mathew PG; McAllister P; Russo AF; Vélez C; Ramajo AP; Abdrabboh A; Xu C; Rasmussen S; Tepper SJ
Neurology; 2022 Nov; 99(19):841-853. PubMed ID: 36127137
[TBL] [Abstract][Full Text] [Related]
2. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
3. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
5. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
6. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
[TBL] [Abstract][Full Text] [Related]
9. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine.
Jinesh S
Inflammopharmacology; 2023 Oct; 31(5):2245-2251. PubMed ID: 37421480
[TBL] [Abstract][Full Text] [Related]
11. Rimegepant: acute treatment for migraine headaches.
Peters GL; Hennessey EK
Pain Manag; 2021 May; 11(3):259-266. PubMed ID: 33550872
[TBL] [Abstract][Full Text] [Related]
12. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
13. Role of CGRP in Migraine.
Edvinsson L
Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
[TBL] [Abstract][Full Text] [Related]
14. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
15. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
Varnado OJ; Hoyt M; Ye W; Nicholson R
Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
de Vries T; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
[TBL] [Abstract][Full Text] [Related]
18. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S
Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430
[TBL] [Abstract][Full Text] [Related]
19. Erenumab in the treatment of migraine.
Jain S; Yuan H; Spare N; Silberstein SD
Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
[TBL] [Abstract][Full Text] [Related]
20. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]